AUTHOR=Hasso-Agopsowicz Mateusz , Crowcroft Natasha , Biellik Robin , Gregory Christopher J. , Menozzi-Arnaud Marion , Amorij Jean-Pierre , Gilbert Philippe-Alexandre , Earle Kristen , Frivold Collrane , Jarrahian Courtney , Mvundura Mercy , Mistilis Jessica J. , Durrheim David N. , Giersing Birgitte 

TITLE=Accelerating the Development of Measles and Rubella Microarray Patches to Eliminate Measles and Rubella: Recent Progress, Remaining Challenges

JOURNAL=Frontiers in Public Health

VOLUME=Volume 10 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2022.809675

DOI=10.3389/fpubh.2022.809675

ISSN=2296-2565

ABSTRACT=Measles and rubella microarray patches (MR-MAPs) are critical in achieving measles and rubella eradication, a goal highly unlikely to meet with current vaccines presentations. With low commercial incentive to MAP developers, limited and uncertain funding, the need for investment in a novel manufacturing facility, and remaining questions about the source of antigen, product demand, and regulatory pathway, MR-MAPs won’t be prequalified by WHO and ready for use before 2033. This article describes the current progress of MR-MAPs, highlights challenges and recommendations pertinent to MR-MAPs manufacturing, regulatory approval, creating demand, and timelines to licensure. It also describes workstreams that are being undertaken to accelerate the development of MR-MAPs.